Merck (NYSE: MRK) today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE